10.04.13
Nexus6 Ltd. has expanded its senior management team.
The New Zealand company recently appointed three new executives in a bid to expand its worldwide commercial operations.
Dr. Veronique Bouchet has been hired as vice president of business development for Europe, Christopher Stevens has been appointed as chief operating officer, and Chris Mander has taken on the role of head of regulatory and quality.
Based in London, United Kingdom, Bouchet will focus on Nexus6’s corporate strategy and drive business development activities in Europe. Bouchet has extensive pharmaceutical industry experience and has held a variety of senior international roles across several therapeutic areas and functions, including strategy, drug development, business development and M&A, most recently with AstraZeneca. Bouchet is the founder of Novudel Associates, a life sciences consulting company; she is a non-executive director of International Biotechnology Trust PLC and of the Stevenage Bioscience Catalyst.
Stevens brings more than 20 years of experience in software product commercialisation for the North American, British, and Australasian markets. Prior to Nexus6 Stevens was global chief technology officer for Orion Health, a leading health information technology company that provides clinical workflow and integration software to the global healthcare sector.
Mander has more than 20 years of experience in the respiratory medical device and patient monitoring industries. Nexus6 executives said his extensive knowledge of the North American, European, and Australasian product approval and compliance processes will bring solid support to the company's future products.
The three new hires follow the February appointment of Dr. Doug Wilson as board chairman. Wilson has decades of experience in the pharmaceutical industry, including a stint as global head of medicine and regulatory affairs at Boehringer Ingelheim.
“This calendar year Nexus6 has assembled a senior leadership team with a unique combination of skills and global experience to drive commercialisation of Nexus6’s products” CEO Garth Sutherland said. “This will ensure that Nexus6 is well positioned for continuing international growth."
Nexus6 is an Auckland-based developer and manufacturer of Smartinhaler respiratory management and asthma devices that provide real-time tracking of medication use and audio-visual reminders that have clinically been proven to significantly increase adherence to preventative medications.
The New Zealand company recently appointed three new executives in a bid to expand its worldwide commercial operations.
Dr. Veronique Bouchet has been hired as vice president of business development for Europe, Christopher Stevens has been appointed as chief operating officer, and Chris Mander has taken on the role of head of regulatory and quality.
Based in London, United Kingdom, Bouchet will focus on Nexus6’s corporate strategy and drive business development activities in Europe. Bouchet has extensive pharmaceutical industry experience and has held a variety of senior international roles across several therapeutic areas and functions, including strategy, drug development, business development and M&A, most recently with AstraZeneca. Bouchet is the founder of Novudel Associates, a life sciences consulting company; she is a non-executive director of International Biotechnology Trust PLC and of the Stevenage Bioscience Catalyst.
Stevens brings more than 20 years of experience in software product commercialisation for the North American, British, and Australasian markets. Prior to Nexus6 Stevens was global chief technology officer for Orion Health, a leading health information technology company that provides clinical workflow and integration software to the global healthcare sector.
Mander has more than 20 years of experience in the respiratory medical device and patient monitoring industries. Nexus6 executives said his extensive knowledge of the North American, European, and Australasian product approval and compliance processes will bring solid support to the company's future products.
The three new hires follow the February appointment of Dr. Doug Wilson as board chairman. Wilson has decades of experience in the pharmaceutical industry, including a stint as global head of medicine and regulatory affairs at Boehringer Ingelheim.
“This calendar year Nexus6 has assembled a senior leadership team with a unique combination of skills and global experience to drive commercialisation of Nexus6’s products” CEO Garth Sutherland said. “This will ensure that Nexus6 is well positioned for continuing international growth."
Nexus6 is an Auckland-based developer and manufacturer of Smartinhaler respiratory management and asthma devices that provide real-time tracking of medication use and audio-visual reminders that have clinically been proven to significantly increase adherence to preventative medications.